Myelodysplastic Syndrome

  • Sandeep GurbuxaniEmail author
Part of the Atlas of Anatomic Pathology book series (AAP)


The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell diseases characterized by cytopenia(s) due to ineffective hematopoiesis accompanied by dysplasia in one or more myeloid cell lines and an increased risk of development of acute leukemia. A correct diagnosis and classification of MDS requires integration of morphology with clinical data and ancillary studies including cytogenetics and next-generation sequencing to detect submicroscopic pathogenic variants. Assessment of morphologic dysplasia relies on review of adequately stained peripheral blood smear, bone core biopsy, and bone marrow aspirate smears. In addition, the blast count is predictive of progression to acute leukemia and should be obtained from a careful assessment of 200 cells in the peripheral blood and 500 cells on the bone marrow aspirate. The chapter summarizes morphologic dysplasia for each of the lineages in the context of the diagnostic criteria for the WHO-defined MDS categories (see Table 10.1 and reference [1]). It is now recognized that cytopenia is invariably implicit in the diagnosis of MDS and the clinical behavior is influenced by the number of dysplastic lineages and the blast count [2]. The WHO revision therefore proposes to change the nomenclature to eliminate the use of refractory anemia and refractory cytopenia and replace it with “myelodysplastic syndrome” with further subclassification relying on the dysplastic lineages and the blast count (Tables 10.1 and 10.2) (Figs. 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 10.10, 10.11, 10.12, 10.13, 10.14, 10.15, 10.16, 10.17, 10.18, 10.19, 10.20, 10.21, 10.22, 10.23, 10.24, 10.25, 10.26, 10.27, 10.28, 10.29, 10.30, 10.31, 10.32, 10.33, 10.34, 10.35, 10.36, 10.37, 10.38, 10.39, and 10.40).




  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMedGoogle Scholar
  2. 2.
    Arber DA, Hasserjian RP. Reclassifying myelodysplastic syndromes: what’s where in the new WHO and why. Hematology Am Soc Hematol Educ Program. 2015;2015:294–8.PubMedGoogle Scholar
  3. 3.
    Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Dusseldorf registry on myelodysplastic syndromes. Leuk Res. 2012;36:727–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Willis MS, Monaghan SA, Miller ML, McKenna RW, Perkins WD, Levinson BS, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123:125–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233–41.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006:199–204.Google Scholar
  8. 8.
    Grossmann V, Bacher U, Haferlach C, Schnittger S, Pötzinger F, Weissmann S, et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. Leukemia. 2013;27:1940–3.CrossRefPubMedGoogle Scholar
  9. 9.
    Willis MS, McKenna RW, Peterson LC, Coad JE, Kroft SH. Low blast count myeloid disorders with Auer rods: a clinicopathologic analysis of 9 cases. Am J Clin Pathol. 2005;124:191–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26:1286–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Baumann I, Führer M, Behrendt S, Campr V, Csomor J, Furlan I, et al. Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria. Histopathology. 2012;61:10–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2011;2011:84–9.PubMedGoogle Scholar
  13. 13.
    Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematology Am Soc Hematol Educ Program. 2016;2016:598–604.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Department of Pathology, Section of HematopathologyUniversity of ChicagoChicagoUSA

Personalised recommendations